{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:23:49Z","timestamp":1789010629276,"version":"build-2803163510"},"reference-count":13,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Problems in Cardiology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.cpcardiol.2025.103100","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T19:54:47Z","timestamp":1750276487000},"page":"103100","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Impact of sodium- glucose co-transporter 2 inhibitors in mortality and Decongestion in cardiac amyloidosis: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-9136-1280","authenticated-orcid":false,"given":"Christiane","family":"Santo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristhian","family":"Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Vaz Kerges Bueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Dabarian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Nativi","family":"Nicolau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.cpcardiol.2025.103100_bib0001","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.cpcardiol.2025.103100_bib0002","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.cpcardiol.2025.103100_bib0003","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.cpcardiol.2025.103100_bib0004","first-page":"1540","article-title":"Sodium-glucose cotransporter-2 inhibitors in transthyretin amyloid cardiomyopathy: rationale and potential clinical implications","volume":"24","author":"Bayes-Genis","year":"2022","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"10.1016\/j.cpcardiol.2025.103100_bib0005","first-page":"1308","article-title":"Efficacy and safety of SGLT2 inhibitors in cardiac amyloidosis: a case series and literature review","volume":"10","author":"Damy","year":"2023","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.cpcardiol.2025.103100_bib0006","first-page":"e21","article-title":"Emerging evidence on the use of SGLT2 inhibitors in cardiac amyloidosis","volume":"9","author":"Martinez-Naharro","year":"2023","journal-title":"Card Fail Rev"},{"key":"10.1016\/j.cpcardiol.2025.103100_bib0007","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.cpcardiol.2025.103100_bib0008","series-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022)","author":"Higgins","year":"2022"},{"issue":"4","key":"10.1016\/j.cpcardiol.2025.103100_bib0009","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1002\/ejhf.3198","article-title":"Sodium-glucose cotransporter 2 inhibitors for transthyretin amyloid cardiomyopathy: analyses of short-term efficacy and safety","volume":"26","author":"Lang","year":"2024","journal-title":"Eur J Heart Fail"},{"issue":"24","key":"10.1016\/j.cpcardiol.2025.103100_bib0010","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1016\/j.jacc.2024.03.429","article-title":"SGLT2 Inhibitor therapy in patients with transthyretin amyloid cardiomyopathy","volume":"83","author":"Porcari","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"19","key":"10.1016\/j.cpcardiol.2025.103100_bib0011","doi-asserted-by":"crossref","first-page":"5966","DOI":"10.3390\/jcm13195966","article-title":"Impact of SGLT2-inhibitor therapy on survival in patients with transthyretin amyloid cardiomyopathy: analysis of a prospective registry study","volume":"13","author":"Schwegel","year":"2024","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.cpcardiol.2025.103100_bib0012","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/ehf2.14188","article-title":"SGLT2 inhibitor therapy for transthyretin amyloid cardiomyopathy: early tolerance and clinical response to dapagliflozin","volume":"10","author":"Dobner","year":"2023","journal-title":"ESC Heart Fail"},{"issue":"12","key":"10.1016\/j.cpcardiol.2025.103100_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2024.101405","article-title":"Sodium-glucose cotransporter 2 inhibitor use and outcomes in transthyretin amyloid cardiomyopathy","volume":"3","author":"Jaiswal","year":"2024","journal-title":"JACC Adv."}],"container-title":["Current Problems in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280625001227?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280625001227?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T08:06:10Z","timestamp":1753689970000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0146280625001227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":13,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0146280625001227"],"URL":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2025.103100","relation":{},"ISSN":["0146-2806"],"issn-type":[{"value":"0146-2806","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of sodium- glucose co-transporter 2 inhibitors in mortality and Decongestion in cardiac amyloidosis: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Current Problems in Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2025.103100","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103100"}}